Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
Ian W FlinnDana S ThompsonRalph V BocciaGerald MiletelloAndrew LipmanDouglas FloraDaniel CuevasSteven W PapishJesus G BerdejaPublished in: British journal of haematology (2017)
This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28%), neutropenia (30%) and lymphopenia (17%). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94% for all patients. The median follow-up was 54 months. Kaplan-Meier estimates of progression-free survival and overall survival at 36 months were 75% and 88%, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.
Keyphrases
- low grade
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- diffuse large b cell lymphoma
- prognostic factors
- high grade
- peritoneal dialysis
- clinical trial
- free survival
- patient reported outcomes
- subarachnoid hemorrhage
- atrial fibrillation
- combination therapy
- multiple myeloma
- smoking cessation
- double blind